All In Biotech

Drug Trial Radar · NCT00870181

ADV-TK Improves Outcome of Recurrent High-Grade Glioma

Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma

Last checked: Nov 20, 2026Latest source record: Jun 25, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Jan 2008

Primary completion

Dec 2011

Study completion Dec 2012

Sponsor

Lead sponsor
Huazhong University of Science and TechnologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing Tiantan Hospital; Beijing Chao Yang Hospital; Beijing Friendship Hospital
First posted
Mar 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and chemotherapy. The advantages of ADV-TK gene therapy highlight its efficacy and safety for glioma patients. This clinical trial was conducted to assess the anti-tumor efficacy and safety of intraarterial cerebral infusion of replication-deficient adenovirus mutant ADV-TK, in combination with systemic intravenous GCV administration in patients with recurrent high-grade glioma.

Conditions

  • Malignant Glioma of Brain
  • Glioblastoma

Interventions

  • ADV-TK/GCVBiological

    gene therapy

  • SurgeryProcedure

  • systemic chemotherapyDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary end point was 6-month progression-free survival rate (PFS-6)Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing YouAn Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.